Clinical Trial Results:
The efficacy and mechanism of surfactant therapy for critically ill infants with bronchiolitis: The Bronchiolitis Endotracheal Surfactant Study (BESS)
|
Summary
|
|
EudraCT number |
2018-001169-18 |
Trial protocol |
GB |
Global end of trial date |
03 Apr 2024
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Nov 2026
|
First version publication date |
13 Nov 2026
|
Other versions |
|
Summary report(s) |
BESS Protocol_V7.0 19.03.2025 Signed.pdf BESS - Final_Analysis_Report_v5.0_20260311.pdf |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
|
Trial identification
|
|||
Sponsor protocol code |
UoL001360
|
||
|
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN11746266 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
IRAS Reference: 220853, REC Reference: 18/SC/0427 | ||
|
Sponsors
|
|||
Sponsor organisation name |
The University of Liverpool
|
||
Sponsor organisation address |
Clinical Directorate, 4th Floor Thompson Yates Building, Faculty of Health and Life Sciences , Liverpool, United Kingdom, L3 5RB
|
||
Public contact |
BESS Trial, Clinical Trials Research Centre (CTRC), 44 0151 795 8757, bess@liverpool.ac.uk
|
||
Scientific contact |
BESS Trial, Clinical Trials Research Centre (CTRC), 44 0151 795 8757, bess@liverpool.ac.uk
|
||
|
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
|
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
13 Dec 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
03 Apr 2024
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
03 Apr 2024
|
||
Was the trial ended prematurely? |
No
|
||
|
General information about the trial
|
|||
Main objective of the trial |
BESS is a study that comprises three work packages. The Trial is Work Package A (WP-A), the parent and staff experience substudy is work package B (WP-B) and the mechanistic substudy is work package C (WP-C).
The hypothesis we are testing in The Trial (WP-A) is: Endotracheal surfactant reduces duration of mechanical ventilation by 18 hours.
This trial will test whether giving surfactant into the lungs of babies suffering from severe bronchiolitis reduces the time they spend on a mechanical ventilator to help them breathe.
We will do this by measuring the total time babies spend on a mechanical ventilator in hours and comparing the time required by babies given a surfactant (called poractant alfa) to babies given air (a dummy or placebo treatment). "18 hours" is included in the hypothesis as this is considered to be the smallest period of time that would be of benefit to a baby's wellbeing. The study will run over 3 winter seasons and involve about 284 babies.
|
||
Protection of trial subjects |
Administration of poractant alfa (porcine derived surfactant, Curosurf®) in infants with bronchiolitis is well tolerated and considered safe. Transient minor adverse reactions associated with administration of poractant alfa for the treatment of neonatal Respiratory Distress Syndrome (RDS) include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. The risk of such events is minimised by tracheal toilet prior to administration of poractant alfa, as recommended in the Summary of Product Characteristics.
Small volume (2x1mL/kg) non-bronchoscopic bronchoalveolar lavage (BAL) procedure on PICU is safe and well tolerated procedure. In a published audit of 27 children on PICU who underwent multiple small volume BAL installations (5x1mL/kg) as part of a single routine diagnostic procedure, 7 experienced transient oxygen desaturation requiring temporary increased FiO2. We will limit BAL sampling to a 2x1mL/kg instillation at each scheduled assessment. BAL sampling for this research study will cease on approval of v5 of this protocol.
Small volume (1.25mL (range 1.0 to 1.3mL)) blood sampling will be done on infants ventilated at Liverpool and Southampton PICUs and scheduled to coincide with routine blood sampling. Existing vascular access will be used when available. There is no risk of anaemia associated with this limited volume of blood sampling. The sample will be taken from an arterial line if present. If not by standard venesection. This additional blood sampling at Liverpool and Southampton PICUs will cease on approval of v5 of this protocol.
Capillary blood gas sampling or arterial blood gas sampling for subject monitoring (100microliters) will use data from routine blood gas sampling when either is collected within a 4-hour (+/-2hrs) window of a research-scheduled sample. As this is part of standard care no additional risks are expected.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Nov 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
|
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 232
|
||
Worldwide total number of subjects |
232
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
6
|
||
Newborns (0-27 days) |
110
|
||
Infants and toddlers (28 days-23 months) |
116
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
||
|
||||||||||||||||
|
Recruitment
|
||||||||||||||||
Recruitment details |
- | |||||||||||||||
|
Pre-assignment
|
||||||||||||||||
Screening details |
1009 patient were screened for eligibility. 391 of these were ineligible at screening, 618 were eligible. Of the 618 eligible at screening patients, 232 were randomised. | |||||||||||||||
|
Pre-assignment period milestones
|
||||||||||||||||
Number of subjects started |
1009 [1] | |||||||||||||||
Number of subjects completed |
232 | |||||||||||||||
|
Pre-assignment subject non-completion reasons
|
||||||||||||||||
Reason: Number of subjects |
Ineligible at screening: 391 | |||||||||||||||
Reason: Number of subjects |
Eligible but not approached: 264 | |||||||||||||||
Reason: Number of subjects |
Declined to participate: 103 | |||||||||||||||
Reason: Number of subjects |
Not randomised: 18 | |||||||||||||||
Reason: Number of subjects |
Incomplete screening log: 1 | |||||||||||||||
| Notes [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: 1009 patient were screened for eligibility. 391 of these were ineligible at screening, 618 were eligible. Of the 618 eligible at screening patients, 232 were randomised i.e. the worldwide number enrolled in the trial. |
||||||||||||||||
|
Period 1
|
||||||||||||||||
Period 1 title |
Baseline (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Carer, Assessor | |||||||||||||||
|
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
|
Arm title
|
Endotracheal poractant alfa | |||||||||||||||
Arm description |
- | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Endotracheal poractant alfa
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Curosurf®
|
|||||||||||||||
Pharmaceutical forms |
Endotracheopulmonary instillation
|
|||||||||||||||
Routes of administration |
Endotracheopulmonary use
|
|||||||||||||||
Dosage and administration details |
Endotracheal poractant alfa (Curosurf®, porcine lung phospholipid fraction supplied at 80mg/mL), first dose 200mg/kg, repeated 12 hourly at 100mg/kg, up to a total of 3 doses according to the manufacturer's summary of product characteristics (SPC).
|
|||||||||||||||
|
Arm title
|
Sham Intervention group | |||||||||||||||
Arm description |
- | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Endotracheopulmonary instillation
|
|||||||||||||||
Routes of administration |
Endotracheopulmonary use
|
|||||||||||||||
Dosage and administration details |
An identical (to the experimental arm) series of up to three procedures (while intubated) using air as the placebo
|
|||||||||||||||
|
||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Endotracheal poractant alfa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Sham Intervention group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
|
End points reporting groups
|
|||
Reporting group title |
Endotracheal poractant alfa
|
||
Reporting group description |
- | ||
Reporting group title |
Sham Intervention group
|
||
Reporting group description |
- | ||
Subject analysis set title |
Endotracheal poractant alfa (Safety set)
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Endotracheal poractant alfa (Safety set)
|
||
Subject analysis set title |
Sham Intervention group (Safety set)
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Sham Intervention group (Safety set)
|
||
Subject analysis set title |
Endotracheal poractant alfa (patient reported readmission)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Patients randomised to Endotracheal poractant alfa and completed the patient reported readmission to hospital.
|
||
Subject analysis set title |
Sham Intervention group (patient reported readmission)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Patients randomised to Sham Intervention group and completed the patient reported readmission to hospital.
|
||
Subject analysis set title |
Endotracheal poractant alfa (baseline weight)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Endotracheal poractant alfa (baseline weight) - 115 of 115 Endotracheal poractant alfa participants had weight measured at baseline, data was unobtainable for 0 participants
|
||
Subject analysis set title |
Sham Intervention group (baseline weight)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Sham Intervention group (baseline weight) - 116 of 117 Sham Intervention group participants had weight measured at baseline, data was unobtainable for 1 participant
|
||
Subject analysis set title |
Endotracheal poractant alfa (baseline time on ventilator)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Endotracheal poractant alfa (baseline time on mechanical ventilator prior to arrival at PICU (hours)) - 111 of 115 Endotracheal poractant alfa participants had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 4 participants.
|
||
Subject analysis set title |
Sham Intervention group (baseline time on ventilator)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Sham Intervention group (baseline time on mechanical ventilator prior to arrival at PICU (hours)) - 116 of 117 Sham Intervention group had time on mechanical ventilator prior to arrival at PICU (hours) measured at baseline, data was unobtainable for 1 participant.
|
||
|
|||||||||||||
End point title |
Primary outcome – Total duration of mechanical ventilation in hours - Time to successful extubation - Median (IQR) | ||||||||||||
End point description |
A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Date/time of randomisation to date/time of successful extubation.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Two-sample t-test for log time on MV in hours | ||||||||||||
Comparison groups |
Sham Intervention group v Endotracheal poractant alfa
|
||||||||||||
Number of subjects included in analysis |
229
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.8625 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.02
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.18 | ||||||||||||
upper limit |
0.21 | ||||||||||||
|
|||||||||||||
End point title |
Primary outcome – Total duration of mechanical ventilation in hours - Time to successful extubation - Median (Range) | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Date/time of randomisation to date/time of successful extubation.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Two-sample t-test for log time on MV in hours | ||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
||||||||||||
Number of subjects included in analysis |
229
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.8625 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.02
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.18 | ||||||||||||
upper limit |
0.21 | ||||||||||||
|
|||||||||||||
End point title |
Primary outcome – Total duration of mechanical ventilation (MV) in hours | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Date/time of randomisation to date/time of successful extubation.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Two-sample t-test for log time on MV in hours | ||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
||||||||||||
Number of subjects included in analysis |
229
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.8625 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.02
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.18 | ||||||||||||
upper limit |
0.21 | ||||||||||||
Statistical analysis title |
Fixed Effects- log time on MV (hours) - Allocation | ||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
||||||||||||
Number of subjects included in analysis |
229
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.8806 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Endotracheal poractant- Treatment effect | ||||||||||||
Point estimate |
0.01
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.17 | ||||||||||||
upper limit |
0.2 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.09
|
||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 1 – Readiness for SBT - Time to readiness for SBT in hours | ||||||||||||
End point description |
A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/time of the observation at which readiness for SBT is first reported.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
||||||||||||||||||||||||||||
End point title |
Secondary outcome 1 – Readiness for SBT - Frequency of the SBT criteria being met per participant | |||||||||||||||||||||||||||
End point description |
||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
Date/time of randomisation to the date/time of the observation at which readiness for SBT is first reported.
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| No statistical analyses for this end point | ||||||||||||||||||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 1 – Readiness for SBT - Two-sample t-test for log time to SBT in hours | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/time of the observation at which readiness for SBT is first reported.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Endotracheal poractant alfa- Sham Intervention | ||||||||||||
Statistical analysis description |
Result for two-sample t-test for log time to SBT in hours
Difference (Endotracheal poractant alfa- Sham Intervention group)
|
||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
||||||||||||
Number of subjects included in analysis |
202
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.9373 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
-0.01
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.29 | ||||||||||||
upper limit |
0.27 | ||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 1 – sensitivity analysis: First SBT criteria - two-sample t-test for time to SBT: sensitivity analysis | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/time of the observation at which readiness for SBT is first reported.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Endotracheal poractant alfa- Sham Intervention | ||||||||||||
Statistical analysis description |
Result for two-sample t-test for time to SBT: sensitivity analysis
Difference (Endotracheal poractant alfa- Sham Intervention group)
|
||||||||||||
Comparison groups |
Sham Intervention group v Endotracheal poractant alfa
|
||||||||||||
Number of subjects included in analysis |
202
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.8994 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
-0.02
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.3 | ||||||||||||
upper limit |
0.27 | ||||||||||||
|
||||||||||||||||||||||
End point title |
Secondary outcome 2 – Number of trial interventions - Frequency of trial interventions | |||||||||||||||||||||
End point description |
A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
add
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Fishers exact | |||||||||||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
|||||||||||||||||||||
Number of subjects included in analysis |
232
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority | |||||||||||||||||||||
P-value |
= 0.3166 | |||||||||||||||||||||
Method |
Fisher exact | |||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 4 – Duration of oxygen supplementation - Time on oxygen supplementation (of any kind) - Mean (S.D.) | ||||||||||||
End point description |
A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date and time of final successful extubation (if this has been observed) to final date and time that any type of oxygen supplementation is ended.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 4 – Duration of oxygen supplementation - Time on oxygen supplementation (of any kind) - Median (IQR) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date and time of final successful extubation (if this has been observed) to final date and time that any type of oxygen supplementation is ended.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 4 – Duration of oxygen supplementation - Time on oxygen supplementation (of any kind) - Median (Range) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date and time of final successful extubation (if this has been observed) to final date and time that any type of oxygen supplementation is ended.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 4 – Duration of oxygen supplementation - Results of two-sample t-test for duration of oxygen supplementation | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date and time of final successful extubation (if this has been observed) to final date and time that any type of oxygen supplementation is ended.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Endotracheal poractant alfa- Sham Intervention | ||||||||||||
Statistical analysis description |
Results of two-sample t-test for duration of oxygen supplementation:
Difference (Endotracheal poractant alfa- Sham Intervention group)
|
||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
||||||||||||
Number of subjects included in analysis |
232
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.0428 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.88
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.03 | ||||||||||||
upper limit |
1.74 | ||||||||||||
|
||||||||||||||||
End point title |
Secondary outcome 5 – Use of steroids to assist extubation - Frequency of steroid use | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
add
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Pearson's Chi-Square test | |||||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
|||||||||||||||
Number of subjects included in analysis |
232
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 0.7044 | |||||||||||||||
Method |
Chi-squared | |||||||||||||||
Parameter type |
Risk ratio (RR) | |||||||||||||||
Point estimate |
1.06
|
|||||||||||||||
Confidence interval |
||||||||||||||||
level |
95% | |||||||||||||||
sides |
2-sided
|
|||||||||||||||
lower limit |
0.79 | |||||||||||||||
upper limit |
1.42 | |||||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 6 - Time on post-extubation respiratory support (non-invasive) - Mean (S.D.) | ||||||||||||
End point description |
A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date and time of final successful extubation (if this has been observed) to final date and time that NIV is ended.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 6 - Time on post-extubation respiratory support (non-invasive) - Median (IQR) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date and time of final successful extubation (if this has been observed) to final date and time that NIV is ended.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 6 - Time on post-extubation respiratory support (non-invasive) - Median (Range) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date and time of final successful extubation (if this has been observed) to final date and time that NIV is ended.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 6 - Results of two-sample t-test for duration of post-extubation respiratory support | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date and time of final successful extubation (if this has been observed) to final date and time that NIV is ended.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Endotracheal poractant alfa- Sham Intervention | ||||||||||||
Statistical analysis description |
Results of two-sample t-test for duration of post-extubation respiratory support:
Difference (Endotracheal poractant alfa- Sham Intervention group)
|
||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
||||||||||||
Number of subjects included in analysis |
232
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.4125 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.52
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.72 | ||||||||||||
upper limit |
1.76 | ||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 7 - Time in PICU - Mean (S.D.) | ||||||||||||
End point description |
A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/ time of discharge from PICU or the date of death if the death occurred before PICU discharge.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 7 - Time in PICU - Median (IQR) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/ time of discharge from PICU or the date of death if the death occurred before PICU discharge.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 7 - Time in PICU - Median (Range) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/ time of discharge from PICU or the date of death if the death occurred before PICU discharge.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 7 - Time in hospital (including both time in PICU and time in hospital) - Mean (S.D.) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/time of hospital discharge or the date of death if death occurred before hospital discharge.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 7 - Time in hospital (including both time in PICU and time in hospital) - Median (IQR) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/time of hospital discharge or the date of death if death occurred before hospital discharge.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 7 - Time in hospital (including both time in PICU and time in hospital) - Median (Range) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/time of hospital discharge or the date of death if death occurred before hospital discharge.
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 7 - Results of two-sample t-test for duration of stay in PICU in hours | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of randomisation to the date/ time of discharge from PICU or the date of death if the death
occurred before PICU discharge.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Endotracheal poractant alfa- Sham Intervention | ||||||||||||
Statistical analysis description |
Results of two-sample t-test for duration of stay in PICU in hours
Difference (Endotracheal poractant alfa- Sham Intervention group)
|
||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
||||||||||||
Number of subjects included in analysis |
230
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.9453 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.01
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.16 | ||||||||||||
upper limit |
0.17 | ||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 7 - Results of two-sample t-test for duration of stay in hospital (post PICU stay) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date/time of discharge from PICU to Date/time of hospital discharge.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Endotracheal poractant alfa- Sham Intervention | ||||||||||||
Statistical analysis description |
Results of two-sample t-test for duration of stay in hospital (post PICU stay)
Difference (Endotracheal poractant alfa- Sham Intervention group)
|
||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
||||||||||||
Number of subjects included in analysis |
227
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.1331 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.12
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.04 | ||||||||||||
upper limit |
0.28 | ||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 8 – Liverpool Respiratory Symptom Questionnaire - Summary of LRSQ data at 6 months - Mean (S.D.) | ||||||||||||
End point description |
A more extensive summary of results for this outcome can be found in the attached BESS - Final_Analysis_Report_v5.0_20260311.pdf.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At 6 months
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 8 – Liverpool Respiratory Symptom Questionnaire - Summary of LRSQ data at 6 months - Median (IQR) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At 6 months
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Secondary outcome 8 – Liverpool Respiratory Symptom Questionnaire - Summary of LRSQ data at 6 months - Median (Range) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At 6 months
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
||||||||||||||||
End point title |
Safety outcome 1 – Failure to administer intervention due to AE - Frequency of trial interventions not delivered due to AE | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Other pre-specified
|
|||||||||||||||
End point timeframe |
add
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Fisher's Exact Test | |||||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
|||||||||||||||
Number of subjects included in analysis |
232
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 0.1202 | |||||||||||||||
Method |
Fisher exact | |||||||||||||||
Confidence interval |
||||||||||||||||
|
||||||||||||||||
End point title |
Safety outcome 2 – Incidence of air leak - Frequency of the total incidences or air leak per participant | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Other pre-specified
|
|||||||||||||||
End point timeframe |
add
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Fisher's Exact Test | |||||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
|||||||||||||||
Number of subjects included in analysis |
232
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 1 | |||||||||||||||
Method |
Fisher exact | |||||||||||||||
Confidence interval |
||||||||||||||||
|
|||||||||||||||||||||||||||||||
End point title |
Safety outcome 3 – Parent reported readmission to hospital - Frequency of the total reported readmissions to hospital | ||||||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||||||||
End point timeframe |
add
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Statistical analysis title |
Fisher's Exact Test | ||||||||||||||||||||||||||||||
Comparison groups |
Endotracheal poractant alfa (patient reported readmission) v Sham Intervention group (patient reported readmission)
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
54
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||
P-value |
= 0.0561 | ||||||||||||||||||||||||||||||
Method |
Fisher exact | ||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
|
||||||||||||||||
End point title |
Safety outcome 4 – Any need to replace the endotracheal tube - Frequency of endotracheal tubes replacements | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Other pre-specified
|
|||||||||||||||
End point timeframe |
add
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Pearson's Chi-Square test | |||||||||||||||
Comparison groups |
Endotracheal poractant alfa v Sham Intervention group
|
|||||||||||||||
Number of subjects included in analysis |
232
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 0.64 | |||||||||||||||
Method |
Chi-squared | |||||||||||||||
Parameter type |
Risk ratio (RR) | |||||||||||||||
Point estimate |
0.87
|
|||||||||||||||
Confidence interval |
||||||||||||||||
level |
95% | |||||||||||||||
sides |
2-sided
|
|||||||||||||||
lower limit |
0.49 | |||||||||||||||
upper limit |
1.55 | |||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Virology – post-hoc request - Virology reported on the discharge CRF | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Post-hoc
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Virology reported on the discharge CRF
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| No statistical analyses for this end point | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
End point title |
Bacteriology – post-hoc request - Bacteriology reported on the discharge CRF | ||||||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||||||
End point type |
Post-hoc
|
||||||||||||||||||||||||||||||
End point timeframe |
Bacteriology reported on the discharge CRF
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||||||||||||||||
|
||||||||||||||||
End point title |
Safety outcome data by safety set – Post hoc - Safety outcome 1 - Frequency of trial interventions not delivered due to AE | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Post-hoc
|
|||||||||||||||
End point timeframe |
add
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Fisher's Exact Test | |||||||||||||||
Comparison groups |
Endotracheal poractant alfa (Safety set) v Sham Intervention group (Safety set)
|
|||||||||||||||
Number of subjects included in analysis |
223
|
|||||||||||||||
Analysis specification |
Post-hoc
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 0.2378 | |||||||||||||||
Method |
Fisher exact | |||||||||||||||
Confidence interval |
||||||||||||||||
|
||||||||||||||||
End point title |
Safety outcome data by safety set – Post hoc - Safety outcome 2 - Frequency of the total incidences or air leak per participant | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Post-hoc
|
|||||||||||||||
End point timeframe |
add
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Fisher's Exact Test | |||||||||||||||
Comparison groups |
Endotracheal poractant alfa (Safety set) v Sham Intervention group (Safety set)
|
|||||||||||||||
Number of subjects included in analysis |
223
|
|||||||||||||||
Analysis specification |
Post-hoc
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 1 | |||||||||||||||
Method |
Fisher exact | |||||||||||||||
Confidence interval |
||||||||||||||||
|
|||||||||||||||||||||||||||||||
End point title |
Safety outcome data by safety set – Post hoc - Safety outcome 3 - Frequency of the total reported readmissions to hospital | ||||||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||||||
End point type |
Post-hoc
|
||||||||||||||||||||||||||||||
End point timeframe |
add
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Statistical analysis title |
Fisher's Exact Test | ||||||||||||||||||||||||||||||
Comparison groups |
Endotracheal poractant alfa (Safety set) v Sham Intervention group (Safety set)
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
54
|
||||||||||||||||||||||||||||||
Analysis specification |
Post-hoc
|
||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||
P-value |
= 0.0561 | ||||||||||||||||||||||||||||||
Method |
Fisher exact | ||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
|
||||||||||||||||
End point title |
Safety outcome data by safety set – Post hoc - Safety outcome 4 – Any need to replace the endotracheal tube | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Post-hoc
|
|||||||||||||||
End point timeframe |
add
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Pearson's Chi-Square test | |||||||||||||||
Comparison groups |
Endotracheal poractant alfa (Safety set) v Sham Intervention group (Safety set)
|
|||||||||||||||
Number of subjects included in analysis |
223
|
|||||||||||||||
Analysis specification |
Post-hoc
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 0.838 | |||||||||||||||
Method |
Chi-squared | |||||||||||||||
Parameter type |
Risk ratio (RR) | |||||||||||||||
Point estimate |
0.94
|
|||||||||||||||
Confidence interval |
||||||||||||||||
level |
95% | |||||||||||||||
sides |
2-sided
|
|||||||||||||||
lower limit |
0.53 | |||||||||||||||
upper limit |
1.68 | |||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
All AEs from randomisation until 24 hrs after last administration of poractant alfa are reported. Related AEs occurring after this time point until 90 days post randomisation / discharge / death are reported. SAEs/SARs are reported regardless of timeframe
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
24.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Endotracheal poractant alfa (Safety set)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Sham Intervention group (Safety set)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||
Substantial protocol amendments (globally) |
|||||||
| Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
31 Jul 2019 |
Amendment from Protocol V2.0 to V3.0 - See section 18.3 of attached BESS Protocol V7.0 for a summary of amendments. |
||||||
24 Nov 2022 |
Amendment from Protocol V3.0 to V4.0 - See section 18.4 of attached BESS Protocol V7.0 for a summary of amendments. |
||||||
07 Feb 2023 |
Amendment from Protocol V4.0 to V5.0 - See section 18.5 of attached BESS Protocol V7.0 for a summary of amendments. |
||||||
Interruptions (globally) |
|||||||
| Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
| Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
| Results for a primary outcome sensitivity analysis and for Secondary outcome 3 - Change over time in blood/ gas measurements are not included in this summary but results are provided in the attached "BESS - Final_Analysis_Report_v5.0_20260311.pdf" | |||||||